EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase IV)

Safety and Diagnostic Performance of Recombinant Fusion Protein ESAT6-CPF10 Skin Test in A Large Population: A Phase 4 Clinical Trial

Junji Chen, Luqing Zhao, Xiang Zhou, Yi Mo, Lanting Kong, Fangli Ma, Liangyong Wu, Dingjin Huang, Huaiyu Yang, Lihui Gong

The Journal of Infectious Diseases · 2025

DOI: 10.1093/infdis/jiaf332 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Infectious Diseases, 2025. Verfasst von Junji Chen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Vaccine Clinical Research, Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention, Nanning, Guangxi Province, China. Hauptthemen laut MEDLINE: Antigens, Bacterial, Bacterial Proteins, Recombinant Fusion Proteins, Tuberculosis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Study on Influencing Factors and Countermeasures of Quality Management of Vaccine Clinical Trials, Anhui Zhifei Longcom Biopharmaceutical Co, Ltd, China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This study aimed to evaluate the safety and diagnostic performance of recombinant fusion protein early secretory antigenic target protein 6–culture filtrate protein 10 (EC) in a community-based population aged ≥6 months.

Methods

We conducted a 2-stage trial in a community-based population. The first stage used a randomized, double-blind, controlled design (n = 500), while the second stage used a nonrandomized, open design (n = 7000). Stage 1 participants underwent tuberculosis-specific enzyme-linked immunospot assay (T-SPOT.TB), tuberculin skin test (TST), and EC skin test (ECST). Stage 2 participants only received the ECST. The purposes of the first and second stage were to evaluate the diagnostic performance and safety of the ECST, respectively.

Results

At the first stage, the sensitivity of ECST and TST was 89.41% (95% confidence interval [CI], 80.85%–95.04%) and 85.88% (95% CI, 76.64%–92.49%), respectively. The specificity of the ECST and TST was 96.98% (95% CI, 94.79%–98.43%%) and 61.06% (95% CI, 56.07%–65.87%), respectively. The consistency between ECST and T-SPOT.TB was higher than that between TST and T-SPOT.TB (κ = 0.85 and 0.28, respectively). At the second stage, the incidence of adverse drug reactions (ADRs) was 11.75%, with 0.67% graded ≥3. The incidence of ADRs varied among age groups (<18 years, 2.89%; 18–64 years, 11.51%; ≥65 years, 16.98%) and was significantly higher in individuals with pulmonary tuberculosis (46.58%), human immunodeficiency virus infection (33.33%), diabetes mellitus (15.56%), close contacts of patients with tuberculosis (14.35%), and those with allergic histories (11.93%).

Conclusions

ECST has a satisfactory safety and diagnostic performance profile and is suitable for screening Mycobacterium tuberculosis infection in the community-based population aged ≥6 months. Clinical Trials Registration. NCT05746611.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antigens, BacterialBacterial ProteinsRecombinant Fusion ProteinsTuberculosisSkin TestsHumansMaleFemaleAdultMiddle AgedDouble-Blind MethodAdolescentYoung AdultTuberculin TestChildChild, PreschoolAgedSensitivity and SpecificityInfantMycobacterium tuberculosisEnzyme-Linked Immunospot Assay

Stichwörter der Autor:innen

ESAT6-CPF10community-based populationdiagnosticssafetytuberculosis

Substanzen

Antigens, BacterialBacterial ProteinsRecombinant Fusion ProteinsESAT-6 protein, Mycobacterium tuberculosis

Autor:innen und Institutionen

  • Institute of Vaccine Clinical Research, Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention, Nanning, Guangxi Province, China.
  • Department of Medical Affairs, Anhui Zhifei Longcom Biopharmaceutical Co, Ltd, Hefei, Anhui Province, China.
  • Institute of Vaccine Clinical Research, Liuzhou Center for Disease Control and Prevention, Liuzhou, Guangxi Province, China.
  • Institute of Vaccine Clinical Research, Liujiang District Center for Disease Control and Prevention, Liuzhou, Guangxi Province, China.

Förderung

  • Study on Influencing Factors and Countermeasures of Quality Management of Vaccine Clinical Trials
  • Anhui Zhifei Longcom Biopharmaceutical Co, Ltd, China

Zitieren

APA

Chen, J., Zhao, L., Zhou, X., Mo, Y., Kong, L., Ma, F., Wu, L., Huang, D., Yang, H., & Gong, L. (2025). Safety and Diagnostic Performance of Recombinant Fusion Protein ESAT6-CPF10 Skin Test in A Large Population: A Phase 4 Clinical Trial. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiaf332

Vancouver

Chen J, Zhao L, Zhou X, Mo Y, Kong L, Ma F, et al. Safety and Diagnostic Performance of Recombinant Fusion Protein ESAT6-CPF10 Skin Test in A Large Population: A Phase 4 Clinical Trial. The Journal of Infectious Diseases. 2025. doi:10.1093/infdis/jiaf332

BibTeX
@article{Chen2025,
  author = {Chen, Junji and Zhao, Luqing and Zhou, Xiang and Mo, Yi and Kong, Lanting and Ma, Fangli and Wu, Liangyong and Huang, Dingjin and Yang, Huaiyu and Gong, Lihui},
  title = {Safety and Diagnostic Performance of Recombinant Fusion Protein ESAT6-CPF10 Skin Test in A Large Population: A Phase 4 Clinical Trial},
  journal = {The Journal of Infectious Diseases},
  year = {2025},
  doi = {10.1093/infdis/jiaf332}
}
Kostenlos starten →